MDNA(Delisted)
Medicenna·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MDNA
Medicenna Therapeutics Corp.
A clinical stage immunotherapy company that develops and commercializes Empowered Cytokines and Superkines for the treatment of cancer
2 Bloor St. W., 7th Floor, Toronto, Ontario M4W 3E2
--
Medicenna Therapeutics Corp. was incorporated as an A2 acquisition company on February 2, 2015 under the Alberta Business Companies Act. The Company is a clinical-stage immuno-oncology company that develops novel, highly selective interleukins (" IL-2 "), interleukin-4 (" IL-4 ") and interleukin-13 modulating cytokines known as "Superkines". These superfactors can either be developed alone as short- or long-term therapeutic drugs, or they can be fused with cell killer proteins to produce authorizing cytokines (" ECs ") that precisely deliver potent toxins to cancer cells without harming adjacent healthy cells.
Company Financials
EPS
MDNA has released its 2024 Q2 earnings. EPS was reported at -0.04, versus the expected -0.05, beating expectations. The chart below visualizes how MDNA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
